Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardioangiologica 2006 October;54(5) > Minerva Cardioangiologica 2006 October;54(5):521-37

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

REVIEWS   

Minerva Cardioangiologica 2006 October;54(5):521-37

Copyright © 2006 EDIZIONI MINERVA MEDICA

language: English

Drug-eluting stents: towards new endpoints

Presbitero P. 1, Zavalloni D. 1, Rossi M. L. 1, Pagnotta P. 1, Belli G. 1, Gasparini G. L. 1, Corrada E. 1, Milone F. 2

1 U.O. Emodinamica e Cardiologia Invasiva Istituto Clinico Humanitas, Milano 2 U.O. Cardiologia, Clinica Cellini, Torino


PDF


Drug-eluting stents (DES) have significantly reduced the rates of in-stent restenosis (ISR). As previously observed with bare-metal stents (BMS), either patient’s clinical characteristics and lesion morphology may influence the risk of recurrence even with DES. In this review we will focus on the most recent available data on clinical settings where DES efficacy on long-term outcomes are largely unknown. In particular, we report on very complex lesions (bifurcations, small vessels, chronic total occlusions, in-stent restenosis) myocardial infarction, multivessel disease, treatment of bypass graft and of unprotected left main disease. Several issues are still open on DES routinary use for these indications, mainly as far as stent thrombosis is concerned. Recent pathological studies show that DES are characterized by chronic inflammatory infiltrates and delayed endothelialization. Therefore, this effect could translate in a “vulnerable period” for thromboses longer than with BMS. Even though large meta-analysis have excluded higher rates of stent thrombosis with DES rather than with BMS, few cases of unusual very late stent thrombosis have been described, pointing out that this problem seems to be still unsolved. Although DES provide better angiographic outcomes in each clinical setting, further randomized studies are running to assess their safety and efficacy on currently off-label indications.

top of page